ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,969.34
0.35%
US Tech 100
20,266.40
0.33%
다우존스 지수
44,296.51
0.97%
Bitcoin
98,584.92
-0.45%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Krystal Biotech Inc (KRYS) 시세

Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

NASDAQ
190.40
8.11
(4.45%)
마감 23 11월 6:00AM
15분 지연
190.40
-0.16
(-0.08%)
시간외 거래: 7:01AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
190.40
매수가
184.44
매도가
190.40
거래량
222,077
182.02 일간 변동폭 191.265
99.00 52주 범위 219.34
market_cap
5.476B
전일 종가
182.29
개장가
184.07
최근 거래 시간
1
@
190.4
마지막 거래 시간
재정 규모
US$ 41,761,160
VWAP
188.0481
평균 볼륨(3m)
229,826
발행 주식
28,760,548
배당수익률
-
주가수익률
501.34
주당순이익(EPS)
0.38
매출
50.7M
순이익
10.93M

Krystal Biotech Inc 정보

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.krystalbio.com
본부
Wilmington, Delaware, USA
설립됨
-
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker KRYS. The last closing price for Krystal Biotech was US$182.29. Over the last year, Krystal Biotech shares have traded in a share price range of US$ 99.00 to US$ 219.34.

Krystal Biotech currently has 28,760,548 shares in issue. The market capitalisation of Krystal Biotech is US$5.24 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 501.34.

KRYS 최신 뉴스

추가 뉴스

Krystal Biotech to Present at Stifel 2024 Healthcare Conference

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

12 11월 2024
GlobeNewswire Inc.

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

06 11월 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

04 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

04 11월 2024
Edgar (US Regulatory)

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health...

04 11월 2024
GlobeNewswire Inc.

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third...

28 10월 2024
GlobeNewswire Inc.

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

13 9월 2024
GlobeNewswire Inc.

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

06 9월 2024
GlobeNewswire Inc.

Form 8-K - Current report

29 8월 2024
Edgar (US Regulatory)

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...

28 8월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
112.046.75039246468178.36190.56168.8751237512176.00386207CS
413.787.80206092175176.62207.84163.6641271701180.00960148CS
12-6.94-3.51677308199197.34207.84163.6641229826182.39573074CS
2622.613.4684147795167.8219.34154.5306621183.29508059CS
5287.8685.6836356544102.54219.3499321696162.97598619CS
156137.71261.3588916352.69219.3438.8563276420116.17505881CS
260138.92269.85236985251.48219.3433.0848224597100.08181624CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83.07M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.48M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.59M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
107.47M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
946.09k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
24.39M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
313.51k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
4M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
415.87M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
229.93M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
155.43M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
154.17M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
103.6M

KRYS Discussion

게시물 보기
Monksdream Monksdream 4 주 전
KRYS. Under $200
👍️0
Monksdream Monksdream 4 월 전
KRYS new 52 week high
👍️0
Monksdream Monksdream 7 월 전
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 8 월 전
KRYS over $30
👍️0
Monksdream Monksdream 9 월 전
KRYS new 52 week high
👍️0
Monksdream Monksdream 1 년 전
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 년 전
Moving nicely today...
👍️0
wiredawg wiredawg 3 년 전
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 년 전
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 년 전
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 년 전
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 년 전
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 년 전
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 년 전
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 년 전
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 년 전
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 년 전
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 년 전
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 년 전
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 년 전
3rd post
👍️0
crudeoil24 crudeoil24 3 년 전
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 년 전
..
👍️0

최근 히스토리

NASDAQ
KRYS
Krystal Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유